Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
NCT07110207 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-08-24
Summary
The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease.
Patients with FTLD often experience olfactory disorders (= sense of smell) and eating disorders: increased appetite, increased food intake and excessive consumption of sugary foods and snacking. This often leads to excessive weight gain. These eating disorders are still poorly understood at present.
In this context, we hypothesise that an alteration in the gustatory pathway - i.e. the way in which the brain perceives taste - could contribute to the eating disorders frequently observed in frontotemporal dementia (FTD), particularly in the marked attraction to sweet foods. We therefore wish to objectively evaluate the taste response to a sweet solution (sucrose) in patients with FTLD, using taste evoked potentials (TEPs). Taste evoked potentials are a reliable and reproducible technique for assessing brain activity in response to taste stimulation. One of their advantages is that they are non-invasive.
This study will document, for the first time in this disease, the characteristics of cortical (brain) processing of taste information.
The FRONTAL-PEG study is an interventional, regional, single-centre study conducted at the Dijon University Hospital, in collaboration with the CMRR (Memory, Resources and Research Centre) and the CSGA (Centre for Taste and Food Sciences).
All investigations are carried out at the CSGA (building adjacent to the Dijon University Hospital), with the exception of blood tests, which are carried out at the Dijon University Hospital.
The total duration of participation in the study is one morning. No follow-up is planned at the end of the study.
Conditions
- Frontotemporal Lobar Degeneration (FTLD)
Interventions
- BIOLOGICAL
-
Blood test
Metabolic measurements and measurements of hormones related to food intake
- OTHER
-
Interrogation of the subject
Collection of socio-demographic data, medical and family history, medication
- OTHER
-
Cognitive assessment
MMSE and MoCA cognitive tests
- OTHER
-
Nutritional assessment
Anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skinfold thickness, brachial circumference), bioelectrical impedance analysis (body fat percentage, lean body mass, body water percentage and bone mass in kg)
- OTHER
-
Taste tests
Recording of PEGs in response to a sucrose solution (prepared beforehand)
- OTHER
-
Sucrose taste detection test
Triangular test
Sponsors & Collaborators
-
Centre Hospitalier Universitaire Dijon
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-18
- Primary Completion
- 2027-08-31
- Completion
- 2027-08-31
Countries
- France
Study Locations
More Related Trials
-
Olfactory Biopsies
NCT07021040 ·Status: RECRUITING ·Phase: NA
-
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
NCT02149160 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
NCT01702480 ·Status: COMPLETED ·Phase: PHASE1
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment
NCT05480358 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
NCT05983575 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
NCT02792179 ·Status: COMPLETED ·Phase: PHASE1
-
Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease
NCT04149860 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment
NCT00530478 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Mild Alzheimer's Disease
NCT03978338 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
NCT02546310 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
NCT00200538 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
NCT01129596 ·Status: COMPLETED
-
Cytokines and Cognitive Decline in Alzheimer's Disease
NCT01351142 ·Status: COMPLETED ·Phase: NA
-
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
NCT03112096 ·Status: COMPLETED ·Phase: PHASE1
-
Enhancing Health and Quality of Life for Individuals With Dementia Through Transitional-State Snacks
NCT05007730 ·Status: COMPLETED ·Phase: NA
-
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease
NCT06677632 ·Status: NOT_YET_RECRUITING
-
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
NCT01044342 ·Status: COMPLETED ·Phase: PHASE1
-
Cognitive Neurology Unit Clinical Registry
NCT05925621 ·Status: RECRUITING
-
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
NCT01429623 ·Status: COMPLETED ·Phase: PHASE2
-
Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial
NCT04489017 ·Status: COMPLETED ·Phase: PHASE2
-
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
NCT01951118 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
NCT01931566 ·Status: TERMINATED ·Phase: PHASE3